Source comparison
Melanotan-2 Cycle Length: Dosing Protocol Comparison
Loading Phase 7–10 days Daily (QD) 0.5–1.0mg/day MC1R receptor saturation; cAMP-PKA pathway activation; initial eumelanin synthesis Required for efficient cycle initiation. Skipping extends time to response by 30–40% Maintenance Phase 8–12 weeks 2–3x weekly 0.
This comparison does not assign a generated winner or score.
- Loading Phase
- 7–10 days
- Daily (QD)
- 0.5–1.0mg/day
- MC1R receptor saturation; cAMP-PKA pathway activation; initial eumelanin synthesis
- Required for efficient cycle initiation. Skipping extends time to response by 30–40%
- Maintenance Phase
- 8–12 weeks
- 2–3x weekly
- 0.25–0.5mg per dose
- Sustained MC1R occupancy above 60% threshold; continued melanogenesis without receptor saturation
- Optimal balance. Maintains response while minimizing desensitization risk
- Extended Maintenance
- Beyond 12 weeks
- Progressive MC1R downregulation (8–10% weekly); diminishing melanogenic response despite stable dosing
- Not recommended. Response declines regardless of dose adjustment
- Washout Period
- 4–8 weeks minimum
- No dosing
- 0mg
- MC1R receptor upregulation; beta-arrestin dissociation; restoration of cell surface receptor density
- Critical for subsequent cycle efficacy. Shorter washouts result in blunted response
- The comparison demonstrates why Melanotan-2 cycle length isn't a single number but a phased protocol. Research applications that treat MT2 as a continuous-use compound rather than a cycled protocol show consistent plateau by week 10–14, while properly structured cycles with adequate washout maintain response consistency across multiple cycles.